Brief: Orexo Announces Positive Data From Phase 1 Clinical Study For OX640

Orexo AB

11/10/2022 07:05

Oct 11 (Reuters) - Orexo AB  ORX.ST :
    * OREXO ANNOUNCES POSITIVE DATA FROM PHASE 1 CLINICAL STUDY
FOR
OX640 - A NASAL EPINEPHRINE RESCUE MEDICATION FOR ALLERGIC
REACTIONS
    * ALL FOUR INVESTIGATIONAL FORMULATIONS OF OX640 WERE
EXTENSIVELY
ABSORBED AND RAPIDLY ACHIEVED CLINICALLY RELEVANT PLASMA LEVELS
OF EPINEPHRINE
    * DATA AVAILABLE TODAY INDICATES SIGNIFICANTLY IMPROVED
STABILITY
COMPARED TO CURRENT STANDARD OF CARE IN A BROAD RANGE OF
TEMPERATURES
    * TARGETED EPINEPHRINE MARKET FOR AUTO-INJECTORS EXCEEDS USD
2
BILLION AND EXPECTS TO SHOW AN ANNUAL GROWTH OF 8-9 PERCENT
    * OREXO WILL SEEK PARTNERSHIPS FOR BOTH CONTINUED
DEVELOPMENT AND
COMMERCIALIZATION

Source text for Eikon:  ID:nWkrbxBdt6 
Further company coverage:  ORX.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))